Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
March 08 2022 - 2:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2022
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 8 March 2022, London UK
GlaxoSmithKline plc
Annual Report 2021 on Form 20-F
In accordance with Section 203.01 of the New York Stock Exchange
Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that
on 8 March 2022 it filed with the Securities and Exchange
Commission an Annual Report on Form 20-F that included audited
financial statements for the year ended 31 December 2021. GSK's
2021 Annual Report on Form 20-F is available online at GSK's
website at www.gsk.com/corporatereporting and
also online at www.sec.gov.
A hard copy version of the GSK 2021 Annual Report, together with
the Notice of Annual General Meeting will be available on or about
28 March 2022.
Shareholders have the ability to receive, upon request, a hard copy
version of GSK's complete audited financial statements for the year
ended 31 December 2021, free of charge, by either:
(i) writing
to Equiniti Limited, our registrars in the UK, at the following
address: Equiniti Limited, Aspect House, Spencer Road,
Lancing, West Sussex BN99 6DA, or by telephone on 0371 384 2991
(inside the UK) or +44 (0)121 415 7067 (outside the
UK);
(ii)
writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the
US, at the following address: EQ Shareowner Services, P.O. Box
64504, St. Paul, MN 55164-0504, or by telephone on +1 800 990 1135
(US toll free) or +1 651 453 2128 (outside the US); or
(iii)
contacting the GSK Response Center in the USA at +1 888 825 5249
(US toll free).
Victoria Whyte
Company
Secretary
8
March 2022
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors" in the company's Annual Report on Form 20-F for
2021.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: March
08, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
